We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Primary Screening Test for Diabetes Reevaluated

By LabMedica International staff writers
Posted on 04 Jan 2012
The blood test for glycosalated hemoglobin, Hb1Ac, has been recently recommended as the primary diagnostic test for diabetes.

The HbA1c blood test is the accepted standard for monitoring long-term glycemic control in patients with diabetes, however until recently, HbA1c was not recommended for diagnosing or screening for diabetes.

In a retrospective study carried out by DynaLIFEDx, Edmonton, AB, Canada) in conjunction with local medical practitioners, evaluated the positive predictive value (PPV) and negative predictive value (NPV) of HbA1c against the oral glucose tolerance test (OGTT) values using a 10% prevalence of diabetes in three locations. DynaLIFEDx is a major Canadian medical laboratory offering a complete range of diagnostic testing services. For a three-year period, 3,163 data pairs were collected including 1,537 males and 1,626 females with a mean age of 55.4 ± 14.7 years. The OGTT criteria for diabetes were found for 568 out of the 3,163 sets.

Blood glucose was measured on the ARCHITECT ci8200 (Abbott Laboratories; Mississauga, ON, Canada) using a hexokinase method and HbA1c was measured by high performance liquid chromatography (HPLC) on a VARIANT II analyzer (Bio-Rad laboratories, Montreal, QC, Canada). The recommended threshold HbA1c value of 6.5% did not give the optimal combination of NPV of 0.93 to 0.92 and PPV of 0.40 to 0.61 compared to a threshold HbA1c value of 7.0% that gave an NPV of 0.91 to 0.92, and PPV of 0.61 to 0.73.

The authors concluded that HbA1c is not satisfactory for use as a diagnostic test for diabetes using the threshold values recommended by the Consensus Committee and the International Expert panel due to low positive predictive values. About 12% of individuals with a normal OGTT test will be diagnosed with diabetes using a threshold HbA1c value of 7.0%. This would put considerable burden on health care resources. However, based on the high negative predictive value, HbA1c may be used as a test to rule-out diabetes. The study was published in the December 2011 issue of the journal Clinical Biochemistry.

Related Links:

DynaLIFEDx
Abbott Laboratories
Bio-Rad



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Centromere B Assay
Centromere B Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.